山东大学耳鼻喉眼学报 ›› 2026, Vol. 40 ›› Issue (1): 106-111.doi: 10.6040/j.issn.1673-3770.0.2024.081

• 综述 • 上一篇    

纳米药物输送系统在变应性鼻炎过敏原免疫治疗中的应用进展

顾敏1,陆美萍1,2   

  1. 1.南京医科大学第一附属医院 耳鼻咽喉科, 江苏 南京 210029;
    2.南京医科大学第一附属医院 耳鼻咽喉科/过敏诊疗中心, 江苏 南京 210029
  • 发布日期:2026-02-13
  • 通讯作者: 陆美萍. E-mail:lumeiping@jsph.org.cn
  • 基金资助:
    江苏省科教能力提升工程(JSDW202203)

Advances in the application of nanomedicine delivery systems in allergen immunotherapy for allergic rhinitis

GU Min1, LU Meiping1,2   

  1. 1. Department of Otorhinolaryngology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China2. Clinical Allergy Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China
  • Published:2026-02-13

PDF (PC)

9

摘要： 变应性鼻炎(allergic rhinitis, AR)是由特应性个体吸入过敏原(如花粉、尘螨、宠物皮屑、霉菌等)后在鼻腔发生的慢性炎症性疾病,在全球范围内的发病率日益增高。过敏原免疫治疗(allergen immunotherapy, AIT)是一种通过调节患者自身免疫功能改变AR自然进程的治疗方法,但其疗效因个体过敏原差异以及免疫作用靶标的不同而存在较大的异质性。纳米材料所具备的特殊理化性质能够更加精确地控制药物释放,保持药物稳定性,减少副作用,并增强免疫调节效果。基于纳米药物输送系统的AIT旨在利用纳米尺度的载体来提高其有效性和安全性,这种新兴技术具有广泛的研究前景,并为AR的治疗提供了新的策略。本文就纳米药物输送系统在AR的过敏原免疫治疗中的应用策略及研究进展作一综述。

关键词: 变应性鼻炎, 过敏原免疫治疗, 纳米技术, 纳米材料, 药物输送系统

Abstract: Allergic rhinitis(AR)is a chronic inflammatory disease occurring in the nasal cavity of atopic individuals following inhalation of allergens such as pollen, dust mites, pet dander, and molds, and is increasing in incidence worldwide. Allergen immunotherapy(AIT)is a treatment that aims to alter the natural course of AR by modulating the patient's own immune function. However, its efficacy varies greatly due to individual allergen differences and the diversity of immune targets. The unique physicochemical properties of nanomaterials allow for more precise control of drug release, maintaining drug stability, reducing side effects, and enhancing immunomodulatory effects. AIT based on nanomedicine delivery systems aims to improve their efficacy and safety using nanoscale carriers. This emerging technology has broad research prospects and offers new strategies for the treatment of AR. This article reviews the application strategies and research progress of nanomedicine delivery systems in allergen immunotherapy for allergic rhinitis.

Key words: Allergic rhinitis, Allergen immunotherapy, Nanotechnology, Nanomaterials, Drug delivery system

中图分类号: 

  • R765.2
[1] Bousquet J, Anto JM, Bachert C, et al. Allergic rhinitis[J]. Nat Rev Dis Primers, 2020, 6(1): 95. doi:10.1038/s41572-020-00227-0
[2] Wise SK, Damask C, RolandLT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis-2023[J]. Int Forum Allergy Rhinol, 2023, 13(4): 293-859. doi:10.1002/alr.23090
[3] Vandenplas O, Vinnikov D, BlancPD, et al. Impact of rhinitis on work productivity: a systematic review[J]. J Allergy Clin Immunol Pract, 2018, 6(4): 1274-1286.e9. doi:10.1016/j.jaip.2017.09.002
[4] Hesse L, Oude Elberink JNG, van Oosterhout AJM, et al. Allergen immunotherapy for allergic airway diseases: use lessons from the past to design a brighter future[J]. Pharmacol Ther, 2022, 237: 108115. doi:10.1016/j.pharmthera.2022.108115
[5] Pfaar O, Richter H, Sager A, et al. Persistence in allergen immunotherapy: a longitudinal, prescription data-based real-world analysis[J]. Clin Transl Allergy, 2023, 13(5): e12245. doi:10.1002/clt2.12245
[6] Ruethers T, Johnston EB, Karnaneedi S, et al. Commercial shellfish skin prick test extracts show critical variability in allergen repertoire[J]. Allergy, 2023, 78(12): 3261-3265. doi:10.1111/all.15853
[7] Rana I, Oh J, Baig J, et al. Nanocarriers for cancer nano-immunotherapy[J]. Drug Deliv Transl Res, 2023, 13(7): 1936-1954. doi:10.1007/s13346-022-01241-3
[8] Bayoumy AB, Crouwel F, Chanda N, et al. Advances in thiopurine drug delivery: the current state-of-the-art[J]. Eur J Drug Metab Pharmacokinet, 2021, 46(6): 743-758. doi:10.1007/s13318-021-00716-x
[9] Moni SS, Abdelwahab SI, Jabeen A, et al. Advancements in vaccine adjuvants: the journey from alum to nano formulations[J]. Vaccines, 2023, 11(11): 1704. doi:10.3390/vaccines11111704
[10] Zhu XD, Li SL. Nanomaterials in tumor immunotherapy: new strategies and challenges[J]. Mol Cancer, 2023, 22(1): 94. doi:10.1186/s12943-023-01797-9
[11] Lee HY, Lee SM, Kang SY, et al. KAAACI guidelines for allergen immunotherapy[J]. Allergy Asthma Immunol Res, 2023, 15(6): 725-756. doi:10.4168/aair.2023.15.6.725
[12] Durham SR, Shamji MH. Allergen immunotherapy: past, present and future[J]. Nat Rev Immunol, 2023, 23(5): 317-328. doi:10.1038/s41577-022-00786-1
[13] Shamji MH, Sharif H, Layhadi JA, et al. Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma[J]. J Allergy Clin Immunol, 2022, 149(3): 791-801. doi:10.1016/j.jaci.2022.01.016
[14] Layhadi JA, Lalioti A, Palmer E, et al. Mechanisms and predictive biomarkers of allergen immunotherapy in the clinic[J]. J Allergy Clin Immunol Pract, 2024, 12(1): 59-66. doi:10.1016/j.jaip.2023.11.027
[15] 杨慧珺, 马行凯. 过敏原免疫治疗的良好临床实践建议[J]. 中华临床免疫和变态反应杂志, 2023, 17(3): 304-305. doi:10.3969/j.issn.1673-8705.2023.03.024 YANG Huijun, MA Xingkai. Suggestions on good clinical practice of allergen immunotherapy[J]. Chinese Journal of Allergy and Clinical Immunology, 2023, 17(3): 304-305. doi:10.3969/j.issn.1673-8705.2023.03.024
[16] Aricigil M, Muluk NB, Sakarya EU, et al. New routes of allergen immunotherapy[J]. Am J Rhinol Allergy, 2016, 30(6): 193-197. doi:10.2500/ajra.2016.30.4379
[17] Incorvaia C, Al-Ahmad M, Ansotegui IJ, et al. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model[J]. Allergy, 2021, 76(4): 1041-1052. doi:10.1111/all.14575
[18] 吴星儒, 刘婉舒, 欧祖镇, 等. 变应性鼻炎经淋巴结注射免疫治疗[J]. 中华临床免疫和变态反应杂志, 2018, 12(2): 194-197. doi:10.3969/j.issn.1673-8705.2018.02.011 WU Xingru, LIU Wanshu, OU Zuzhen, et al. Intralymphatic immunotherapy in allergic rhinitis[J]. Chinese Journal of Allergy and Clinical Immunology, 2018, 12(2): 194-197. doi:10.3969/j.issn.1673-8705.2018.02.011
[19] Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections[J]. J Allergy Clin Immunol, 2012, 129(5): 1290-1296. doi:10.1016/j.jaci.2012.02.026
[20] Jiang SJ, Xie SB, Tang QP, et al. Evaluation of intralymphatic immunotherapy in allergic rhinitis patients: a systematic review and meta-analysis[J]. Mediators Inflamm, 2023, 2023: 9377518. doi:10.1155/2023/9377518
[21] Wang QX, Wang K, Qin Y, et al. Intra-cervical lymphatic immunotherapy for dust mite-induced allergic rhinoconjunctivitis in children: a 3-year prospective randomized controlled trial[J]. Front Immunol, 2023, 14: 1144813. doi:10.3389/fimmu.2023.1144813
[22] Kasemsuk N, Ngaotepprutaram P, Kanjanawasee D, et al. Local nasal immunotherapy for allergic rhinitis: a systematic review and meta-analysis[J]. Int Forum Allergy Rhinol, 2022, 12(12): 1503-1516. doi:10.1002/alr.23011
[23] Kanjanawasee D, Tantilipikorn P. LNIT-Local nasal immunotherapy in allergic rhinitis: revisited evidence and perspectives[J]. Curr Opin Allergy Clin Immunol, 2022, 22(4): 259-267. doi:10.1097/ACI.0000000000000830
[24] Kehagia E, Papakyriakopoulou P, Valsami G. Advances in intranasal vaccine delivery: a promising non-invasive route of immunization[J]. Vaccine, 2023, 41(24): 3589-3603. doi:10.1016/j.vaccine.2023.05.011
[25] Langer R. Drug delivery and targeting[J]. Nature, 1998, 392(6679 Suppl): 5-10
[26] Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions[J]. Molecules, 2021, 26(19): 5905. doi:10.3390/molecules26195905
[27] Shi JJ, Kantoff PW, Wooster R, et al. Cancer nanomedicine: progress, challenges and opportunities[J]. Nat Rev Cancer, 2017, 17(1): 20-37. doi:10.1038/nrc.2016.108
[28] Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect[J]. Adv Drug Deliv Rev, 2011, 63(3): 136-151. doi:10.1016/j.addr.2010.04.009
[29] Brudno Y, Pezone MJ, Snyder TK, et al. Replenishable drug depot to combat post-resection cancer recurrence[J]. Biomaterials, 2018, 178: 373-382. doi:10.1016/j.biomaterials.2018.05.005
[30] Azharuddin M, Zhu GH, Sengupta A, et al. Nano toolbox in immune modulation and nanovaccines[J]. Trends Biotechnol, 2022, 40(10): 1195-1212. doi:10.1016/j.tibtech.2022.03.011
[31] Lin G, Wang J, Yang YG, et al. Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance[J]. Front Bioeng Biotechnol, 2023, 11: 1242126. doi: 10.3389/fbioe.2023.1242126
[32] Lin YJ, Zimmermann J, Schülke S. Novel adjuvants in allergen-specific immunotherapy: where do we stand [J] Front Immunol, 2024, 15: 1348305. doi: 10.3389/fimmu.2024.1348305
[33] Nagy NA, de Haas AM, Geijtenbeek TBH, et al. Therapeutic liposomal vaccines for dendritic cell activation or tolerance[J]. Front Immunol, 2021, 12: 674048. doi:10.3389/fimmu.2021.674048
[34] Keshavarz Shahbaz S, Varasteh AR, Koushki K, et al. Sublingual dendritic cells targeting by aptamer: possible approach for improvement of sublingual immunotherapy efficacy[J]. Int Immunopharmacol, 2020, 85: 106603. doi:10.1016/j.intimp.2020.106603
[35] Macri C, Dumont C, Johnston AP, et al. Targeting dendritic cells: a promising strategy to improve vaccine effectiveness[J]. Clin Transl Immunology, 2016, 5(3): e66. doi:10.1038/cti.2016.6
[36] Simpson JD, Ray A, Marcon C, et al. Single-molecule analysis of SARS-CoV-2 binding to C-type lectin receptors[J]. Nano Lett, 2023, 23(4): 1496-1504. doi:10.1021/acs.nanolett.2c04931
[37] Aljabali AA, Obeid MA, Bashatwah RM, et al. Nanomaterials and their impact on the immune system[J]. Int J Mol Sci, 2023, 24(3): 2008. doi:10.3390/ijms24032008
[38] Lin PH, Cao MD, Xia F, et al. A phosphatase-mimetic nano-stabilizer of mast cells for long-term prevention of allergic disease[J]. Adv Sci, 2021, 8(8): 2004115. doi:10.1002/advs.202004115
[39] Scotland BL, Shaw JR, Dharmaraj S, et al. Cell and biomaterial delivery strategies to induce immune tolerance[J]. Adv Drug Deliv Rev, 2023, 203: 115141. doi:10.1016/j.addr.2023.115141
[40] Liu Q, Wang X, Liu XS, et al. Use of polymeric nanoparticle platform targeting the liver to induce treg-mediated antigen-specific immune tolerance in a pulmonary allergen sensitization model[J]. ACS Nano, 2019, 13(4): 4778-4794. doi:10.1021/acsnano.9b01444
[41] Saito E, Gurczynski SJ, Kramer KR, et al. Modulating lung immune cells by pulmonary delivery of antigen-specific nanoparticles to treat autoimmune disease[J]. Sci Adv, 2020, 6(42): eabc9317. doi:10.1126/sciadv.abc9317
[42] Zhao TM, Cai YL, Jiang YJ, et al. Vaccine adjuvants: mechanisms and platforms[J]. Signal Transduct Target Ther, 2023, 8(1): 283. doi:10.1038/s41392-023-01557-7
[43] Roth GA, Picece VCTM, Ou BS, et al. Designing spatial and temporal control of vaccine responses[J]. Nat Rev Mater, 2022, 7(3): 174-195. doi:10.1038/s41578-021-00372-2
[44] Roth GA, Gale EC, Alcántara-Hernández M, et al. Injectable hydrogels for sustained codelivery of subunit vaccines enhance humoral immunity[J]. ACS Cent Sci, 2020, 6(10): 1800-1812. doi:10.1021/acscentsci.0c00732
[45] O'Hagan DT, van der Most R, Lodaya RN, et al. “World in motion” - emulsion adjuvants rising to meet the pandemic challenges[J]. NPJ Vaccines, 2021, 6(1): 158. doi:10.1038/s41541-021-00418-0
[46] van Strien J, Warmenhoven H, Logiantara A, et al. Betv1-displaying elastin-like polypeptide nanoparticles induce a strong humoral and weak CD4+ T-cell response against Betv1 in a murine immunogenicity model[J]. Front Immunol, 2022, 13: 1006776. doi:10.3389/fimmu.2022.1006776
[47] Balenga NA, Zahedifard F, Weiss R, et al. Protective efficiency of dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy[J]. J Biotechnol, 2006, 124(3): 602-614. doi:10.1016/j.jbiotec.2006.01.014
[48] Shahgordi S, Sankian M, Yazdani Y, et al. Immune responses modulation by curcumin and allergen encapsulated into PLGA nanoparticles in mice model of rhinitis allergic through sublingual immunotherapy[J]. Int Immunopharmacol, 2020, 84: 106525. doi:10.1016/j.intimp.2020.106525
[49] Smarr CB, Yap WT, Neef TP, et al. Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization[J]. Proc Natl Acad Sci U S A, 2016, 113(18): 5059-5064. doi:10.1073/pnas.1505782113
[50] Krieg AM. CpG motifs in bacterial DNA and their immune effects[J]. Annu Rev Immunol, 2002, 20: 709-760. doi:10.1146/annurev.immunol.20.100301.064842
[51] Hanagata N. CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies[J]. Int J Nanomedicine, 2017, 12: 515-531. doi: 10.2147/IJN.S114477
[52] Yang X, Su B, Liu J, et al. A CpG-oligodeoxynucleotide suppresses Th2/Th17 inflammation by inhibiting IL-33/ST2 signaling in mice from a model of adoptive dendritic cell transfer of smoke-induced asthma[J]. Int J Mol Sci, 2023, 24(4): 3130. doi: 10.3390/ijms24043130
[53] Zhou J, Deng GM. The role of bacterial DNA containing CpG motifs in diseases[J]. J Leukoc Biol, 2021, 109(5): 991-998. doi: 10.1002/JLB.3MR1220-748RRRRR
[54] Liu W, Ota M, Tabushi M, et al. Development of allergic rhinitis immunotherapy using antigen-loaded small extracellular vesicles[J]. J Control Release, 2022, 345: 433-442. doi:10.1016/j.jconrel.2022.03.016
[55] Sun SC. The non-canonical NF-κB pathway in immunity and inflammation[J]. Nat Rev Immunol, 2017, 17: 545-558. doi:10.1038/nri.2017.52
[56] Karri U, Harasimowicz M, Carpio Tumba M, et al. The complexity of Being A20: from biological functions to genetic associations[J]. J Clin Immunol, 2024, 44(3): 76. doi: 10.1007/s10875-024-01681-1
[57] Hu WH, Ma L, Yang G, et al. Der p2-A20 DNA vaccine attenuates allergic inflammation in mice with allergic rhinitis[J]. Mol Med Rep, 2019, 20(6): 4925-4932. doi:10.3892/mmr.2019.10760
[58] Jewell CM, Bustamante López SC, Irvine DJ. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles[J]. Proc Natl Acad Sci USA, 2011, 108(38): 15745-15750. doi:10.1073/pnas.1105200108
[1] 吕倩,唐源,顾子君,施赛磊,刘萍,万文锦. 变应性鼻炎患者疾病获益感现状及影响因素分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 21-28.
[2] 秦娜娜,李玉芬,孙雨浩,魏健,李钦. 基于TGF-β1/Smad信号通路探讨白细胞介素13受体α2对变应性鼻炎大鼠鼻黏膜组织重塑的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 71-77.
[3] 熊琴, 张砚, 乌日娜, 李锋, 唐力行. 鼻用糖皮质激素在儿童中的应用[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 160-167.
[4] 王晓杰,张明君,宋哲莹,崔丽梅,宋西成. 山奈酚抗癌的作用机制及研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 168-178.
[5] 许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33.
[6] 刘怡君,谷悦,官大宇,杨玉成,沈暘. 翼管神经切断术在难治性变应性鼻炎中远期临床疗效和安全性[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 42-48.
[7] 张婷,王美兰,高映勤. 白细胞介素35在变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 139-147.
[8] 张竹萍,彭孜灿,肖振龙,李程,喻迪,王兴龙,陈伟,郭蓓. 新型鼻分泌物嗜酸粒细胞阳离子蛋白-髓过氧化物酶试纸在变应性鼻炎中的应用价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 129-134.
[9] 刘畅,杨景朴,高雨,王文佳. 长春地区儿童变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 51-58.
[10] 周荷青,申琪. 中医药治疗变应性鼻炎疗效的生物标志物研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 168-176.
[11] 王曼娴,郑泉,杨亮. 细菌裂解物治疗变应性鼻炎的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 141-145.
[12] 刘畅,方宏艳,刘敩,富东娜,王贺,王晶,杨景朴. 长春地区秋季变应性鼻炎蒿属花粉致敏特征分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 13-19.
[13] 朱朗,刘志奇. 移动医疗提供的真实世界数据在变应性鼻炎治疗方案中的参考[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 135-139.
[14] 张静祎,董湘依,牟亚魁,宋西成. 细胞焦亡在耳鼻咽喉科疾病中的研究进展[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 140-148.
[15] 张丽净,冯晓星,刘南仙,赵辉明,陈月华. 石墨烯养护鼻罩结合尘螨的皮下特异性免疫治疗在尘螨变应性鼻炎患者中的应用分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 26-32.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发